Method of inhibiting progression of type 1 diabetes by administering soluble CD137
US8673844B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2012 |
| Grant date | Mar 18, 2014 |
| Priority date | — |
| Expiry date | Oct 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/599
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating or preventing a T-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells. Also provided are pharmaceutical compositions for treating or preventing T-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells and a pharmaceutically-acceptable carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.